Individualized Homeopathic Medicinal Products in the Treatment of Post-COVID-19 Conditions: A Double-Blind, Randomized, Placebo-Controlled, Feasibility Trial
Evidence suggests that post-coronavirus disease 2019 (COVID-19) is associated with reduced health-related quality of life, and up to 80% of those infected with COVID-19 may experience these symptoms. The objective of the present study was to identify the effects of individualized homeopathic medicin...
Saved in:
Published in | Journal of integrative and complementary medicine |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
25.09.2024
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Summary: | Evidence suggests that post-coronavirus disease 2019 (COVID-19) is associated with reduced health-related quality of life, and up to 80% of those infected with COVID-19 may experience these symptoms. The objective of the present study was to identify the effects of individualized homeopathic medicinal products (IHMPs) against placebos in postCOVID-19 conditions.
Double-blind, randomized (1:1), two parallel arms, placebo-controlled, feasibility trial.
D. N. De Homoeopathic Medical College & Hospital, Kolkata, West Bengal, India.
Sixty participants with post-COVID-19 conditions.
Group verum (
= 30; IHMPs plus concomitant care) versus group control (
= 30; placebos plus concomitant care).
Feasibility issues; primary-post-COVID-19 symptoms checklist; secondary-Measure Yourself Medical Outcomes Profile version 2 (MYMOP-2); all of them were measured at baseline, and monthly intervals, up to 3 months. The intention-to-treat sample was analyzed; group differences were reported using descriptive statistics: means, 95% confidence intervals (CIs), and between group effect sizes (Cohen's
).
Feasibility concerns showed promise; recruitment, retention, and attrition rates were 34.2%, 95%, and 5%, respectively. Group differences in both primary and secondary outcomes favored IHMPs against placebos: symptoms checklist score mean difference after 3 months: -4.2, 95% CI -4.9 to -3.4,
= 2.854 and MYMOP-2 mean difference after 3 months: -2.2, 95% CI -2.8 to -1.7,
= 2.082, respectively.
(11.7%),
(10%),
(8.3%), and
(8.3%) were the most frequently prescribed remedies.
IHMPs produced better results than placebos in reducing symptoms checklist scores and MYMOP-2 scores in the treatment of post-COVID-19 conditions. Definitive trials are warranted to confirm the findings. |
---|---|
ISSN: | 2768-3613 |
DOI: | 10.1089/jicm.2024.0102 |